Additionally, either hormone receptor positive tumor treated with endocrine therapy or HER2 positive tumor treated with anti-HER2 therapy showed superior OS outcomes than others (Table 2, Additional file 1: Table S2). This evidence concerns the gene NR4A1 and neoplasm.